No Data
No Data
Institutional Owners May Ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) Recent US$92m Market Cap Decline as Longer-term Profits Stay in the Green
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40
Stifel analyst Bradley Canino maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 44.2% an
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.0% and a total average return of 23.7% over th
Express News | HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior an
Express News | Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
104016428 : will that mean that after their presentation on June 1 it might fly high on monday? or when the news is out for ASCO that's the end of the rally